Stay updated with breaking news from Concomitant Use. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
An unprecedented 60% of patients remain alive without disease progression after five years Updated results show continued 81% reduction in risk of progression or death and 94% reduction in...
THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two sodium glucose transport
Commercial launch of INPEFA® continues to progress. with increasing demand across the cardiology community and improving payer access Patient enrollment underway in PROGRESS, a Phase 2b study of...
(2023-11-12 | NDAQ:LXRX) INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data
Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and separately in MACE related outcomes as early as approximately three months in patients at high risk for cardiovascular events INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure THE WOODLANDS, Texas, Nov. 12, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today